The book targets new advances in areas of treatment and drug delivery sciences for tuberculosis. It covers advances in drug therapy and drug targeting that focus on innovative trend defining technologies and drug delivery platforms in the understanding of host-pathogens relationship for providing better therapy. A wide variety of novel and nano-formulations using promising technologies are being explored to deliver the drug via different administration routes. This book It addresses the gap between new approaches and old treatment modalities and how they are superior in pharmacological performance when tested in in-vitro and in-vivo. Audience from wide range group like from researchers to regulatory bodies can benefit from the compiled information to find out patient needs and current research advances in the field of tuberculosis research. .

Nanotechnology can treat diseases by site-specific and target-oriented delivery of precise medicines. Nanomaterials improve the efficacy of drugs and selective diagnosis. The book covers detection and treatment. It explains the use of nanocarriers for a variety of diseases such as cardiovascular and respiratory diseases, cancer, and ulcerative colitis. It includes topical, transdermal, and ocular drug delivery and combined medication delivery.

Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems explores the development of novel therapeutics and diagnostics to improve pulmonary disease management, looking down to the nanoscale level for an efficient system of targeting and managing respiratory disease. The book examines numerous nanoparticle-based drug systems such as nanocrystals, dendrimers, polymeric micelles, protein-based, carbon nanotube, and liposomes that can offer advantages over traditional drug delivery systems. Starting with a brief introduction on different types of nanoparticles in respiratory disease conditions, the book then focuses on current trends in disease pathology that use different in vitro and in vivo models. The comprehensive resource is designed for those new to the field and to specialized scientists and researchers involved in pulmonary research and drug development. - Explores recent perspectives and challenges regarding the management and diagnosis of chronic respiratory diseases - Provides insights into how advanced drug delivery systems can be effectively formulated and delivered for the management of various pulmonary diseases - Includes the most recent information on diagnostic methods and treatment strategies using controlled drug delivery systems (including nanotechnology)

Cutting edge technology-based drug delivery systems have been rapidly growing and are being applied to various sections of biomedicine. The current scenario of global burden due to infectious disorders can take advantage of nanoparticulate based carriers to advance the cure efficiency. Nanostructured Drug Delivery Systems in Infectious Disease Treatment explores a broad range of promising approaches for the treatment of infectious diseases using the latest advancements in nanomedical technologies. The book opens with introduction about infectious diseases and its global burden. There is also specific discussion and assessment of the global impact of viruses with an emphasis on COVID-19, Zika, and Ebola. Subsequent chapters provide detailed information about various novel nanotherapeutic strategies used for delivering drugs for the treatment of various types of viral, bacterial, and fungal disorders. Nanostructured Drug Delivery Systems in Infectious Disease Treatment is a valuable resource for graduates, researchers, industry professionals, and anyone working to tackle the challenges of delivering drugs in a more targeted and efficient manner for the treatment of infectious diseases. - Focuses on the application of different nanotechnology-based drug delivery systems - Offers information on how to design and develop the nanotechnology-based drug delivery systems and devices for the treatment of infectious disorders - Explores challenges and regulatory concerns of nanomedicine in infectious disorders

Handbook of Lung Targeted Drug Delivery Systems: Recent Trends and Clinical Evidences covers every aspect of the drug delivery to lungs, the physiology and pharmacology of the lung, modelling for lung delivery, drug devices focused on lung treatment, regulatory requirements, and recent trends in clinical applications. With the advent of nano sciences and significant development in the nano particulate drug delivery systems there has been a renewed interest in the lung as an absorption surface for various drugs. The emergence of the COVID-19 virus has brought lung and lung delivery systems into focus, this book covers new developments and research used to address the prevention and treatment of respiratory diseases. Written by well-known scientists with years of experience in the field this timely handbook is an excellent reference book for the scientists and industry professionals. Key Features: Focuses particularly on the chemistry, clinical pharmacology, and biological developments in this field of research. Presents comprehensive information on emerging nanotechnology applications in diagnosing and treating pulmonary diseases Explores drug devices focused on lung treatment, regulatory requirements, and recent trends in clinical applications Examines specific formulations targeted to pulmonary systems

Provides a review of novel pharmaceutical approaches for Tuberculosis drugs Presents a novel perspective on tuberculosis prevention and treatment Considers the nature of disease, immunological responses, vaccine and drug delivery, disposition and response Multidisciplinary appeal, with contributions from microbiology, immunology, molecular biology, pharmaceutics, pharmacokinetics, chemical and mechanical engineering

The disability-adjusted life year (DALY) is a generic measure of health effect that can be used in cost-effectiveness analysis as an alternative to the quality-adjusted life year (QALY). Infectious diseases are one of the major to cause significant losses of DALY and QALY. Human infectious diseases are disorders that are triggered by the micro-organisms such as bacteria, fungi, viruses, or parasites. The majority of such diseases are contagious and create a public health menace. There are several reasons why infectious diseases are deadly diseases, and one of the primary reasons is the drug resistance developed over time. Drug resistance-associated mutations are linked to increasing drug efflux, modifications of the drugs, or their targets. Every year, new drugs are being approved by FDA to treat infectious diseases. Nonetheless, the infectious diseases will undoubtedly persist as permanent and main threats to humanity for now and in the future. A total of four books are covered under the series of Infectious drug diseases. - Malarial drug delivery systems - Tubercular drug delivery systems - Viral drug delivery systems - Infectious disease drug delivery systems Infectious diseases are the world’s greatest killers that present one of the most significant health and security challenges. Humans have lived with emerging and re-emerging pathogens since before the documented history of civilization. The only determining fact today is - If the situation is “worse” or “better” than in past. The answer is probably “worse”, may be due significant increase in human population, increased cross-continent mobility, imbalanced (stressed) life style, irregular food habits leading to compromised innate immunity and over or under practiced hygiene routine. When the incidence of such a disease in people increases over 20 years or threatens to increase, it is called an “emerging” disease, and a growing number have made watch lists and headlines in nearly every country -like highly pathogenic H5N1 avian influenza, severe acute respiratory syndrome (SARS), Ebola virus, food- and waterborne illnesses, and a range of antimicrobial-resistant bacterial diseases TB. This book addresses current and new therapy developments in treating such infectious diseases, updates on finding new drugs, identification of innovative diagnostic methods, understanding of disease research models and clinical trials performances of new treatment modalities. Audiences from a broad range of groups, from researchers, academicians, and public health bodies to regulatory experts, can benefit from the compiled information to learn more about patient needs and current research advances in the field of infectious diseases and related research.

This book comprehensively reviews the recent developments of natural polymers for drug delivery systems in various lung disorders. The initial chapter provides a brief introduction to lung diseases with a focus on the current landscape of natural polymers and trends in understanding the disease pathology. Several chapters of the book devoted to the latest technologies and advances in drug delivery systems include practical solutions on designing more effective drug delivery systems based on natural polymers that can be used in the management of lung diseases. Further, the book presents biodegradable and bio-reducible- natural polymers- based drug delivery systems for lung diseases. Towards the end, the book examines future prospects and challenges of natural polymers-based drug delivery systems in combating lung diseases. This book is useful for phytochemists, formulation/drug delivery, biological and translational researchers and clinicians working in the field of lung disorders.

Long-Acting Drug Delivery Systems: Pharmaceutical, Clinical, and Regulatory Aspects

Nanotechnology Based Approaches for Tuberculosis Treatment discusses multiple nanotechnology-based approaches that may help overcome persisting limitations of conventional and traditional treatments. The book summarizes the types of nano drugs, their synthesis, formulation, characterization and applications, along with the most important administration routes. It also explores recent advances and achievements regarding therapeutic efficacy and provides possible future applications in this field. It will be a useful resource for investigators, pharmaceutical researchers, innovators and scientists working on technology advancements in the areas of targeted therapies, nano scale imaging systems, and diagnostic modalities in tuberculosis. - Addresses the gap between nanomedicine late discovery and early development of tuberculosis therapeutics - Explores tuberculosis nanomedicine standardization and characterization with newly developed treatment, diagnostic and treatment monitoring modalities - Covers the field thoroughly, from the pathogenesis of tuberculosis and multi-drug resistant mycobacterium tuberculosis, to treatment approaches using nanotechnology and different nanocarriers